Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imraldi

- PMLiVE

AZ gets early FDA green light for Imbruvica challenger

Sets up a marketing battle with Johnson/AbbVie

- PMLiVE

AbbVie risankizumab trials set up psoriasis filing – and a market battle

Competes against blockbusters Stelara and Humira

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

AbbVie and Roche plan Venclexta combo filings in leukaemia

MURANO trial shows the duo’s treatment extends PFS

- PMLiVE

Sandoz says Humira biosimilar clears clinical hurdle

Its drug matches the safety and efficacy of AbbVie’s plaque psoriasis blockbuster

Biogen Idec building

Biogen says trial extension data keep Alzheimer’s drug on track

Releases updated results from the PRIME trial of anti-amyloid drug aducanumab

- PMLiVE

New EU and US approvals for Humira biosimilars

Samsung’s Imraldi and Boehringer Ingelheim’s Cyltezo receives nod from EMA and FDA, respectively

- PMLiVE

Samsung deal with Takeda looks beyond biosimilars

The duo plan to develop “multiple novel biologic therapies”

- PMLiVE

Biogen expands digital safety platform Assessa

The MS technolgy pilot, a collaboration with Ixico, will now include pharmacoviglance reporting

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

- PMLiVE

Merck & Co’s Remicade biosimilar undercuts its US rivals

Its version will be 35% cheaper than J&J's originator product

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links